Macrophage cytokines: Involvement in immunity and infectious diseases

Frontiers in Immunology

Volumn 5, Issue OCT, 2014, Pages

  Duque, Guillermo Arango ^a,b   Descoteaux, Albert ^a,b  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b Department of Microbiology and Immunology   (Canada)

Author keywords

Anti inflammatory; Cytokine; Exocytosis; Leishmania; Macrophage; Mycobacterium ulcerans; Proinflammatory; Trafficking

Indexed keywords

CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN; VASCULOTROPIN C;

ADAPTIVE IMMUNITY; ALLERGY; AUTOPHAGY; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENDOSOME; EPSTEIN BARR VIRUS; EXOCYTOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; LEISHMANIA; MACROPHAGE; MACROPHAGE ACTIVATION; METASTASIS; MONOCYTE; MYCOBACTERIUM ULCERANS; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SCHIZOPHRENIA; TUMOR GROWTH; UPREGULATION; YEAST;

EID: 84918809100     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00491     Document Type: Review

References (128)

1. Tauber AI. Metchnikoff and the phagocytosis theory. Nat Rev Mol Cell Biol (2003) 4(11):897-901. doi: 10.1038/nrm1244
2. Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages. Science (2013) 342(6161):1242974. doi:10.1126/science.1242974
3. Huber C, Stingl G. Macrophages in the regulation of immunity. Haematol Blood Transfus (1981) 27:31-7.
4. Unanue ER, Beller DI, Calderon J, Kiely JM, Stadecker MJ. Regulation of immunity and inflammation by mediators from macrophages. Am J Pathol (1976) 85(2):465-78.
5. Dinarello CA. Historical insights into cytokines. Eur J Immunol (2007) 37(Suppl 1):S34-45. doi:10.1002/eji.200737772
6. Bernheim HA, Kluger MJ. Fever and antipyresis in the lizard Dipsosaurus dorsalis. Am J Physiol (1976) 231(1):198-203.
7. Huynh KK, Kay JG, Stow JL, Grinstein S. Fusion, fission, and secretion during phagocytosis. Physiology (Bethesda) (2007) 22:366-72. doi:10.1152/physiol.00028.2007
8. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 11(10):889-96. doi:10.1038/ni.1937
9. Stow JL, Murray RZ. Intracellular trafficking and secretion of inflammatory cytokines. Cytokine Growth Factor Rev (2013) 24(3):227-39. doi:10.1016/j.cytogfr.2013.04.001
10. Stow JL, Manderson AP, Murray RZ. SNAREing immunity: the role of SNAREs in the immune system. Nat Rev Immunol (2006) 6(12):919-29. doi:10.1038/nri1980
11. Arango Duque G, Fukuda M, Descoteaux A. Synaptotagmin XI regulates phagocytosis and cytokine secretion in macrophages. J Immunol (2013) 190(4):1737-45. doi:10.4049/jimmunol.1202500
12. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl (1999) 57:16-21.
13. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 72(9):3666-70. doi:10.1073/pnas.72.9.3666
14. Griffin GK, Newton G, Tarrio ML, Bu D-X, Maganto-Garcia E, Azcutia V, et al. IL-17 and TNF-a sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J Immunol (2012) 188(12):6287-99. doi:10.4049/jimmunol.1200385
15. Vieira SM, Lemos HP, Grespan R, Napimoga MH, Dal-Secco D, Freitas A, et al. A crucial role for TNF-a in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br J Pharmacol (2009) 158(3):779-89. doi:10.1111/j.1476-5381.2009.00367.x
16. Sozzani S, Abbracchio MP, Annese V, Danese S, De Pita O, De Sarro G, et al. Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity (2014) 47(5):287-306. doi:10.3109/08916934.2014.897333
17. Murray RZ, Kay JG, Sangermani DG, Stow JL. A role for the phagosome in cytokine secretion. Science (2005) 310(5753):1492-5. doi:10.1126/science.1120225
18. Pagan JK, Wylie FG, Joseph S, Widberg C, Bryant NJ, James DE, et al. The t-SNARE syntaxin 4 is regulated during macrophage activation to function in membrane traffic and cytokine secretion. Curr Biol (2003) 13(2):156-60. doi:10.1016/S0960-9822(03)00006-X
19. Murray RZ, Wylie FG, Khromykh T, Hume DA, Stow JL. Syntaxin 6 and Vti1b form a novel SNARE complex, which is up-regulated in activated macrophages to facilitate exocytosis of tumor necrosis factor-alpha. J Biol Chem (2005) 280(11):10478-83. doi:10.1074/jbc.M414420200
20. Stanley AC, Wong CX, Micaroni M, Venturato J, Khromykh T, Stow JL, et al. The Rho GTPase Rac1 is required for recycling endosome-mediated secretion of TNF in macrophages. Immunol Cell Biol (2014) 92(3):275-86. doi:10.1038/icb.2013.90
21. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 385(6618):729-33. doi:10.1038/385729a0
22. Arango Duque G, Fukuda M, Turco SJ, Stäger S, Descoteaux A. Leishmania promastigotes induce cytokine secretion in macrophages through the degradation of synaptotagmin XI. J Immunol (2014) 193(5):2363-72. doi:10.4049/jimmunol.1303043
23. Baram D, Adachi R, Medalia O, Tuvim M, Dickey BF, Mekori YA, et al. Synaptotagmin II negatively regulates Ca2+-triggered exocytosis of lysosomes in mast cells. J Exp Med (1999) 189(10):1649-58. doi:10.1084/jem.189.10.1649
24. Czibener C, Sherer NM, Becker SM, Pypaert M, Hui E, Chapman ER, et al. Ca2+ and synaptotagmin VII-dependent delivery of lysosomal membrane to nascent phagosomes. J Cell Biol (2006) 174(7):997-1007. doi:10.1083/jcb.200605004
25. Vinet AF, Fukuda M, Descoteaux A. The exocytosis regulator synaptotagmin V controls phagocytosis in macrophages. J Immunol (2008) 181(8):5289-95. doi:10.4049/jimmunol.181.8.5289
26. Südhof TC. Calcium control of neurotransmitter release. Cold Spring Harb Perspect Biol (2012) 4(1):a011353. doi:10.1101/cshperspect.a011353
27. Wang Z, Chapman ER. Rat and Drosophila synaptotagmin 4 have opposite effects during SNARE-catalyzed membrane fusion. J Biol Chem (2010) 285(40):30759-66. doi:10.1074/jbc.M110.137745
28. Milochau A, Lagree V, Benassy MN, Chaignepain S, Papin J, Garcia-Arcos I, et al. Synaptotagmin 11 interacts with components of the RNA-induced silencing complex RISC in clonal pancreatic beta-cells. FEBS Lett (2014) 588(14):2217-22. doi:10.1016/j.febslet.2014.05.031
29. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A (2009) 106(17):7119-24. doi:10.1073/pnas.0902745106
30. Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol (2009) 183(7):4705-14. doi:10.4049/jimmunol.0901511
31. Yazdi AS, Guarda G, Riteau N, Drexler SK, Tardivel A, Couillin I, et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci U S A (2010) 107(45):19449-54. doi:10.1073/pnas.1008155107
32. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med (2007) 13(7):851-6. doi:10.1038/nm1603
33. Ravikumar B, Futter M, Jahreiss L, Korolchuk VI, Lichtenberg M, Luo S, et al. Mammalian macroautophagy at a glance. J Cell Sci (2009) 122(Pt 11):1707-11. doi:10.1242/jcs.031773
34. Duran JM, Anjard C, Stefan C, Loomis WF, Malhotra V. Unconventional secretion of Acb1 is mediated by autophagosomes. J Cell Biol (2010) 188(4):527-36. doi:10.1083/jcb.200911154
35. Dupont N, Jiang S, Pilli M, Ornatowski W, Bhattacharya D, Deretic V. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1ß. EMBO J (2011) 30(23):4701-11. doi:10.1038/emboj.2011.398
36. Jiang S, Dupont N, Castillo EF, Deretic V. Secretory versus degradative autophagy: unconventional secretion of inflammatory mediators. J Innate Immun (2013) 5(5):471-9. doi:10.1159/000346707
37. Brough D, Rothwell NJ. Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. J Cell Sci (2007) 120(Pt 5):772-81. doi:10.1242/jcs.03377
38. Marty V, Medina C, Combe C, Parnet P, Amedee T. ATP binding cassette transporter ABC1 is required for the release of interleukin-1beta by P2×7-stimulated and lipopolysaccharide-primed mouse Schwann cells. Glia (2005) 49(4):511-9. doi:10.1002/glia.20138
39. Qu Y, Franchi L, Nunez G, Dubyak GR. Non-classical IL-1ß secretion stimulated by P2×7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol (2007) 179(3):1913-25. doi:10.4049/jimmunol.179.3.1913
40. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol (2004) 4(4):386-91. doi:10.1016/j.coph.2004.03.005
41. Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg RP, Dorsch M, et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med (2011) 39(6):1407-13. doi:10.1097/CCM.0b013e318211ff56
42. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 14(6):705-14. doi:10.1016/S1074-7613(01)00151-0
43. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 1813(5):878-88. doi:10.1016/j.bbamcr.2011.01.034
44. Matthews VB, Allen TL, Risis S, Chan MHS, Henstridge DC, Watson N, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia (2010) 53(11):2431-41. doi:10.1007/s00125-010-1865-y
45. Manderson AP, Kay JG, Hammond LA, Brown DL, Stow JL. Subcompartments of the macrophage recycling endosome direct the differential secretion of IL-6 and TNFalpha. J Cell Biol (2007) 178(1):57-69. doi:10.1083/jcb.200612131
46. Dorman SE, Holland SM. Interferon-? and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev (2000) 11(4):321-33. doi:10.1016/S1359-6101(00)00010-1
47. Croxford AL, Kulig P, Becher B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev (2014) 25(4):415-21. doi:10.1016/j.cytogfr.2014.07.017
48. Wang KS, Frank DA, Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood (2000) 95(10):3183-90.
49. Duitman EH, Orinska Z, Bulfone-Paus S. Mechanisms of cytokine secretion: a portfolio of distinct pathways allows flexibility in cytokine activity. Eur J Cell Biol (2011) 90(6-7):476-83. doi:10.1016/j.ejcb.2011.01.010
50. Logan MR, Lacy P, Odemuyiwa SO, Steward M, Davoine F, Kita H, et al. A critical role for vesicle-associated membrane protein-7 in exocytosis from human eosinophils and neutrophils. Allergy (2006) 61(6):777-84. doi:10.1111/j.1398-9995.2006.01089.x
51. Mollinedo F, Calafat J, Janssen H, Martín-Martín B, Canchado J, Nabokina SM, et al. Combinatorial SNARE complexes modulate the secretion of cytoplasmic granules in human neutrophils. J Immunol (2006) 177(5):2831-41. doi:10.4049/jimmunol.177.5.2831
52. Pulecio J, Petrovic J, Prete F, Chiaruttini G, Lennon-Dumenil A-M, Desdouets C, et al. Cdc42-mediated MTOC polarization in dendritic cells controls targeted delivery of cytokines at the immune synapse. J Exp Med (2010) 207(12):2719-32. doi:10.1084/jem.20100007
53. Gatti S, Beck J, Fantuzzi G, Bartfai T, Dinarello CA. Effect of interleukin-18 on mouse core body temperature. Am J Physiol Regul Integr Comp Physiol (2002) 282(3):R702-9. doi:10.1152/ajpregu.00393.2001
54. Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA. Differences in signaling pathways by IL-1ß and IL-18. Proc Natl Acad Sci U S A (2004) 101(23):8815-20. doi:10.1073/pnas.0402800101
55. Vanden Eijnden S, Goriely S, De Wit D, Willems F, Goldman M. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol (2005) 35(2):469-75. doi:10.1002/eji.200425677
56. Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity (2001) 15(4):569-78. doi:10.1016/S1074-7613(01)00206-0
57. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7(9):937-45. doi:10.1038/ni1376
58. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev (2008) 226(1):205-18. doi:10.1111/j.1600-065X.2008.00706.x
59. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol (1991) 147(11):3815-22.
60. Chadban SJ, Tesch GH, Foti R, Lan HY, Atkins RC, Nikolic-Paterson DJ. Interleukin-10 differentially modulates MHC class II expression by mesangial cells and macrophages in vitro and in vivo. Immunology (1998) 94(1):72-8. doi:10.1046/j.1365-2567.1998.00487.x
61. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med (1992) 175(3):671-82. doi:10.1084/jem.175.3.671
62. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A (1992) 89(5):1890-3. doi:10.1073/pnas.89.5.1890
63. Oswald IP, Wynn TA, Sher A, James SL. Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation. Proc Natl Acad Sci U S A (1992) 89(18):8676-80. doi:10.1073/pnas.89.18.8676
64. Cunha FQ, Moncada S, Liew FY. Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. Biochem Biophys Res Commun (1992) 182(3):1155-9. doi:10.1016/0006-291X(92)91852-H
65. Varzaneh FN, Keller B, Unger S, Aghamohammadi A, Warnatz K, Rezaei N. Cytokines in common variable immunodeficiency as signs of immune dysregulation and potential therapeutic targets - a review of the current knowledge. J Clin Immunol (2014) 34(5):524-43. doi:10.1007/s10875-014-0053-0
66. Stanley AC, Lieu ZZ, Wall AA, Venturato J, Khromykh T, Hamilton NA, et al. Recycling endosome-dependent and -independent mechanisms for IL-10 secretion in LPS-activated macrophages. J Leukoc Biol (2012) 92(6):1227-39. doi:10.1189/jlb.0412191
67. Travis MA, Sheppard D. TGF-ß activation and function in immunity. Annu Rev Immunol (2014) 32:51-82. doi:10.1146/annurev-immunol-032713-120257
68. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, et al. TGF-ß suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 21(4):491-501. doi:10.1016/j.immuni.2004.07.020
69. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol (2012) 30:531-64. doi:10.1146/annurev.immunol.25.022106.141623
70. Gleizes PE, Munger JS, Nunes I, Harpel JG, Mazzieri R, Noguera I, et al. TGF-ß latency: biological significance and mechanisms of activation. Stem Cells (1997) 15(3):190-7. doi:10.1002/stem.150190
71. Comerford I, McColl SR. Mini-review series: focus on chemokines. Immunol Cell Biol (2011) 89(2):183-4. doi:10.1038/icb.2010.164
72. Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J Exp Med (1990) 171(5):1797-802. doi:10.1084/jem.171.5.1797
73. Pelus LM, Fukuda S. Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. Exp Hematol (2006) 34(8):1010-20. doi:10.1016/j.exphem.2006.04.004
74. Addison CL, Arenberg DA, Morris SB, Xue YY, Burdick MD, Mulligan MS, et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum Gene Ther (2000) 11(2):247-61. doi:10.1089/10430340050015996
75. Donlon TA, Krensky AM, Wallace MR, Collins FS, Lovett M, Clayberger C. Localization of a human T-cell-specific gene, RANTES (D17S136E), to chromosome 17q11.2-q12. Genomics (1990) 6(3):548-53. doi:10.1016/0888-7543(90)90485-D
76. Maghazachi AA, Al-Aoukaty A, Schall TJ. CC chemokines induce the generation of killer cells from CD56+ cells. Eur J Immunol (1996) 26(2):315-9. doi:10.1002/eji.1830260207
77. Han C, Chen T, Yang M, Li N, Liu H, Cao X. Human SCAMP5, a novel secretory carrier membrane protein, facilitates calcium-triggered cytokine secretion by interaction with snare machinery. J Immunol (2009) 182(5):2986-96. doi:10.4049/jimmunol.0802002
78. Gouwy M, Struyf S, Catusse J, Proost P, Van Damme J. Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. J Leukoc Biol (2004) 76(1):185-94. doi:10.1189/jlb.1003479
79. Starckx S, Van den Steen PE, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization. Leuk Lymphoma (2002) 43(2):233-41. doi:10.1080/10428190290005982
80. Van Damme J, Struyf S, Opdenakker G. Chemokine-protease interactions in cancer. Semin Cancer Biol (2004) 14(3):201-8. doi:10.1016/j.semcancer.2003.10.007
81. Gijsbers K, Van Assche G, Joossens S, Struyf S, Proost P, Rutgeerts P, et al. CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur J Immunol (2004) 34(7):1992-2000. doi:10.1002/eji.200324807
82. Rosenblum JM, Shimoda N, Schenk AD, Zhang H, Kish DD, Keslar K, et al. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors. J Immunol (2010) 184(7):3450-60. doi:10.4049/jimmunol.0903831
83. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol (2008) 28(11):1928-36. doi:10.1161/ATVBAHA.108.162925
84. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol (2002) 168(7):3195-204. doi:10.4049/jimmunol.168.7.3195
85. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med (1998) 187(12):2009-21. doi:10.1084/jem.187.12.2009
86. Gundra UM, Girgis NM, Ruckerl D, Jenkins S, Ward LN, Kurtz ZD, et al. Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct. Blood (2014) 123:e110-22. doi:10.1182/blood-2013-08-520619
87. Zhang W, Xu W, Xiong S. Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J Immunol (2010) 184(11):6465-78. doi:10.4049/jimmunol.0904016
88. Lu J, Cao Q, Zheng D, Sun Y, Wang C, Yu X, et al. Discrete functions of M2a and M2c macrophage subsets determine their relative efficacy in treating chronic kidney disease. Kidney Int (2013) 84(4):745-55. doi:10.1038/ki.2013.135
89. Weng M, Huntley D, Huang I-F, Foye-Jackson O, Wang L, Sarkissian A, et al. Alternatively activated macrophages in intestinal helminth infection: effects on concurrent bacterial colitis. J Immunol (2007) 179(7):4721-31. doi:10.4049/jimmunol.179.7.4721
90. Hao N-B, Lü M-H, Fan Y-H, Cao Y-L, Zhang Z-R, Yang S-M. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol (2012) 2012:11. doi:10.1155/2012/948098
91. Ong S-M, Tan Y-C, Beretta O, Jiang D, Yeap W-H, Tai JJY, et al. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. Eur J Immunol (2012) 42(1):89-100. doi:10.1002/eji.201141825
92. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol (2002) 161(3):947-56. doi:10.1016/S0002-9440(10)64255-1
93. Sibley LD. Invasion and intracellular survival by protozoan parasites. Immunol Rev (2011) 240(1):72-91. doi:10.1111/j.1600-065X.2010.00990.x
94. Flannagan RS, Cosio G, Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol (2009) 7(5):355-66. doi:10.1038/nrmicro2128
95. Walsh DS, Portaels F, Meyers WM. Buruli ulcer: advances in understanding Mycobacterium ulcerans infection. Dermatol Clin (2011) 29(1):1-8. doi:10.1016/j.det.2010.09.006
96. George KM, Pascopella L, Welty DM, Small PLA. Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun (2000) 68(2):877-83. doi:10.1128/IAI.68.2.877-883.2000
97. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science (1999) 283(5403):854-7. doi:10.1126/science.283.5403.854
98. Demangel C, Stinear TP, Cole ST. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol (2009) 7(1):50-60. doi:10.1038/nrmicro2077
99. Hall B, Simmonds R. Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer. Biochem Soc Trans (2014) 42(1):177-83. doi:10.1042/BST20130133
100. Simmonds RE, Lali FV, Smallie T, Small PLC, Foxwell BM. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol (2009) 182(4):2194-202. doi:10.4049/jimmunol.0802294
101. Torrado E, Adusumilli S, Fraga AG, Small PLC, Castro AG, Pedrosa J. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun (2007) 75(8):3979-88. doi:10.1128/IAI.00290-07
102. Hall BS, Hill K, McKenna M, Ogbechi J, High S, Willis AE, et al. The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER. PLoS Pathog (2014) 10(4):e1004061. doi:10.1371/journal.ppat.1004061
103. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One (2012) 7(5):e35671. doi:10.1371/journal.pone.0035671
104. Kedzierski L. Leishmaniasis vaccine: where are we today? J Glob Infect Dis (2010) 2(2):177-85. doi:10.4103/0974-777X.62881
105. Moradin N, Descoteaux A. Leishmania promastigotes: building a safe niche within macrophages. Front Cell Infect Microbiol (2012) 2:121. doi:10.3389/fcimb.2012.00121
106. Lodge R, Descoteaux A. Leishmania invasion and phagosome biogenesis. Subcell Biochem (2008) 47:174-81. doi:10.1007/978-0-387-78267-6_14
107. Real F, Florentino PTV, Reis LC, Ramos-Sanchez EM, Veras PST, Goto H, et al. Cell-to-cell transfer of Leishmania amazonensis amastigotes is mediated by immunomodulatory LAMP-rich parasitophorous extrusions. Cell Microbiol (2014) 16(10):1549-64. doi:10.1111/cmi.12311
108. Yao C. Major surface protease of trypanosomatids: one size fits all? Infect Immun (2010) 78(1):22-31. doi:10.1128/IAI.00776-09
109. Joshi PB, Kelly BL, Kamhawi S, Sacks DL, McMaster WR. Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol Biochem Parasitol (2002) 120(1):33-40. doi:10.1016/S0166-6851(01)00432-7
110. Matheoud D, Moradin N, Bellemare-Pelletier A, Shio MT, Hong WJ, Olivier M, et al. Leishmania evades host immunity by inhibiting antigen cross-presentation through direct cleavage of the SNARE VAMP8. Cell Host Microbe (2013) 14(1):15-25. doi:10.1016/j.chom.2013.06.003
111. Gómez MA, Contreras I, Halle M, Tremblay ML, McMaster RW, Olivier M. Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases. Sci Signal (2009) 2(90):ra58. doi:10.1126/scisignal.2000213
112. Jaramillo M, Gómez MA, Larsson O, Shio MT, Topisirovic I, Contreras I, et al. Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. Cell Host Microbe (2011) 9(4):331-41. doi:10.1016/j.chom.2011.03.008
113. Hallé M, Gómez MA, Stuible M, Shimizu H, McMaster WR, Olivier M, et al. The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation. J Biol Chem (2009) 284(11):6893-908. doi:10.1074/jbc.M805861200
114. Contreras I, Gómez MA, Nguyen O, Shio MT, McMaster RW, Olivier M. Leishmania-induced inactivation of the macrophage transcription factor AP-1 is mediated by the parasite metalloprotease GP63. PLoS Pathog (2010) 6(10):e1001148. doi:10.1371/journal.ppat.1001148
115. Ghosh J, Bose M, Roy S, Bhattacharyya SN. Leishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. Cell Host Microbe (2013) 13(3):277-88. doi:10.1016/j.chom.2013.02.005
116. Descoteaux A, Moradin N, Arango Duque G. Leishmania dices away cholesterol for survival. Cell Host Microbe (2013) 13(3):245-7. doi:10.1016/j.chom.2013.02.018
117. Arena A, Capozza AB, Delfino D, Iannello D. Production of TNFa and interleukin 6 by differentiated U937 cells infected with Leishmania major. New Microbiol (1997) 20(3):233-40.
118. Matte C, Olivier M. Leishmania-induced cellular recruitment during the early inflammatory response: modulation of proinflammatory mediators. J Infect Dis (2002) 185(5):673-81. doi:10.1086/339260
119. Lapara NJ III, Kelly BL. Suppression of LPS-induced inflammatory responses in macrophages infected with Leishmania. J Inflamm (Lond) (2010) 7(1):8. doi:10.1186/1476-9255-7-8
120. Wenzel UA, Bank E, Florian C, Forster S, Zimara N, Steinacker J, et al. Leishmania major parasite stage-dependent host cell invasion and immune evasion. FASEB J (2012) 26(1):29-39. doi:10.1096/fj.11-184895
121. Karam MC, Hamdan HG, Abi Chedid NA, Bodman-Smith KB, Eales-Reynolds LJ, Baroody GM. Leishmania major: low infection dose causes short-lived hyperalgesia and cytokines upregulation in mice. Exp Parasitol (2006) 113(3):168-73. doi:10.1016/j.exppara.2006.01.003
122. Jones MR, Quinton LJ, Simms BT, Lupa MM, Kogan MS, Mizgerd JP. Roles of interleukin-6 in activation of STAT proteins and recruitment of neutrophils during Escherichia coli Pneumonia. J Infect Dis (2006) 193(3):360-9. doi:10.1086/499312
123. Biswas P, Delfanti F, Bernasconi S, Mengozzi M, Cota M, Polentarutti N, et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood (1998) 91(1):258-65.
124. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med (2001) 194(10):1497-506. doi:10.1084/jem.194.10.1497
125. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in Leishmaniasis. J Immunol (2001) 166(2):1141-7. doi:10.4049/jimmunol.166.2.1141
126. Ribeiro-Gomes FL, Roma EH, Carneiro MBH, Doria NA, Sacks DL, Peters NC. Site dependent recruitment of inflammatory cells determines the effective dose of Leishmania major. Infect Immun (2014) 82(7):2713-27. doi:10.1128/IAI.01600-13
127. + regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice. PLoS Negl Trop Dis (2012) 6(8):e1798. doi:10.1371/journal.pntd.0001798
128. 3+ cells produce IL-10 in the spleens of dogs with visceral leishmaniasis. Vet Parasitol (2014) 202(3-4):313-8. doi:10.1016/j.vetpar.2014.03.010